Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥487.00 - ¥764.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)27.73K

Market Cap

¥6.13B

Enterprise Value¥3.38K

Total Cash (Recent Filing)¥3.39B

Total Debt (Recent Filing)¥1.23B

Price to Earnings (P/E)―

Beta0.28

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-81.38

Shares Outstanding10,092,100

10 Day Avg. Volume35,320

30 Day Avg. Volume27,726

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue ReboundThe sharp 2025 revenue rebound indicates renewed demand for the company’s offerings and provides a stronger base for future operating leverage. If growth continues, greater platform utilization could help spread fixed costs and support progress toward commercial scale over the next several quarters.

Specialized Regenova PlatformA focused platform serving 3D cellular construct fabrication gives Cyfuse a defined position at the intersection of bioengineering, life-science research, and advanced manufacturing. Continued adoption by research and therapeutic-development users could create durable technology-led growth opportunities.

Manageable LeverageDebt remains moderate relative to the company’s equity base, while total assets have grown. This balance-sheet position provides some capacity to continue developing the platform and supporting operations, although maintaining that flexibility depends on reducing losses and limiting additional borrowing.

Bears Say

Deep Persistent LossesThe scale and duration of operating and net losses show that the business has not yet established a scalable cost structure. Even with revenue recovery, expenses remain far above sales, creating substantial execution risk and making sustained profitability dependent on significant operating improvement.

Negative Free Cash FlowPersistent cash outflows mean the company cannot currently fund operations and development from internally generated cash. Continued negative free cash flow increases reliance on external capital, limits financial flexibility, and raises the risk that growth investments will require dilution or additional financing.

Rising Debt Amid LossesHigher debt alongside continuing losses increases financing pressure even though leverage remains below 0.5 times equity. If profitability and cash generation do not improve, additional borrowing could become more costly or constrained, reducing the resources available for platform development.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥487.00 and its highest was ¥764.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥6.13B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is Nov 12, 2026 which is in 59 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on Aug 14, 2026. The company reported -¥20.9 earnings per share for the quarter.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 10,092,100 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥20.9 in its last earnings report. Following the earnings report the stock price went up 1.633%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.